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Growth factors and cytokines such as the platelet-derived
growth factor (PDGF) have the potential to mediate many
biologic responses of glomerular cells, particularly mesangial
cells [1]. Peptide growth factors including PDGF possess di-
verse biologic properties highly relevant to glomerular pathol-
ogy [21. Biologic effects of PDGF may include promotion of
hypertrophy and proliferation, regulation of matrix metabolism,
vasoactive properties, regulation of immune-inflammatory re-
sponses such as chemotaxis, activation or deactivation of
inflammatory cells, and a role in development and differentia-
tion.
Mesangial cells are frequently involved in the course of
glomerular injury first as target cells for a variety of mediators
released locally or delivered through the systemic circulation
[1]. Activated mesangial cells may then assume an effector cell
function resulting in resolution or progression of a given patho-
logic lesion. For example, proliferation of mesangial cells, a
common manifestation of glomerular disease, may contribute to
progression of glomerular injury through several mechanisms
[11. On the other hand, migration and proliferation of these cells
may help repopulate glomerular cells after cell lysis or necrosis,
thereby restoring glomerular integrity. PDGF is a prime candi-
date to mediate or modulate biologic responses of mesangial
cells (Table 1). Biologically active PDGF is a disulphide linked
dimer composed of two polypeptides designated A and B chains
[3, 4]. The two chains share 40% homology but are encoded by
two separate genes. PDGF exists as a heterodimer, PDGF AB
or as homodimers PDGF AA or PDGF BB. Among several
peptide growth factors, PDGF stands out as the most potent
mitogen for mesangial cells. Both PDGF isoforms, PDGF-BB
as well as the heterodimer PDGF-AB, promote this mitogenic
effect. Unlike its effect on balb 3T3 cells, PDGF is a complete
mitogen for mesangial cells that is able to induce competence as
well as progression. There is little information concerning signal
transduction mechanisms elicited by PDGF in mesangial cells.
Activation of phosphalipase C with subsequent generation of
1P3 and increase in cytosolic calcium have been demonstrated
in response to PDGF in mesangial cells [5]. Since neutralization
of phosphatidylinositol 4,5-bisphosphate by antibody microin-
jection blocks the mitogenic response to PDGF, it is likely that
this represents one important pathway by which PDGF medi-
ates its mitogenic effect. The generation of diacylglycerol in
response to PDGF via activating protein kinase C could also
mediate or modulate the mitogenic effect of PDGF in mesangial
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cells since phorbol esters, activators of protein kinase C, are
potent mitogens for mesangial cells [6—8]. Autoactivation of
PDGF A and B chain mRNA in response to PDGF BB or AB
have been demonstrated in human mesangial cells [71. We have
shown that multiple peptide growth factors, in addition to
PDGF itself, also induce PDGF A and B chain mRNA in
mesangial cells. The mechanisms by which PDGF or these
other peptide growth factors stimulate PDGF mRNA remain to
be elucidated. In several other tissues, these growth factors
generate phosphatidic acid and increase phosphatidic acid mass
albeit via different mechanisms. Our recent finding that phos-
phatidic acid is a potent inducer of PDGF mRNA suggests that
phosphatidic acid accumulation in response to these peptide
growth factors may be an important mediator that activates
PDGF in response to PDGF itself or in response to other
peptides [8]. This possibility is particularly intriguing since
many of these peptides transduce different signals proximal to
the generation of phosphatidic acid in mesangial cells.
Mesangial cells not only respond to PDGF but they are also
a source of this peptide [9, 101. Mesangial cells isolated from
glomeruli of several species produce PDGF activity (Table 2).
Utilizing receptor assay we found that rat mesangial cells
secrete the highest amount of PDGF, followed by mouse and
human mesangial cells. Mesangial cells also express PDGF A
and B chain mRNAs. Serum as well as purified recombinant
growth factors not only stimulate DNA synthesis in mesangial
cells, but also induce PDGF A and B chain mRNAs as de-
scribed earlier. Table 3 lists the biologically relevant com-
pounds that have been shown to stimulate PDGF or PDGF gene
expression in mesangial cells. The PDGF isoform secreted by
mesangial cells constitutively or in response to these substances
remains to be determined. It is likely that PDGF AA ho-
modimer represents the major PDGF isoform secreted since the
cells express very high amounts of PDGF A chain mRNA
compared to B chain mRNA. This is also likely to be the case
since PDGF A chain is more efficiently secreted than the B
chain [31. However, in several established cell lines, the relative
distribution of PDGF A or B chain genes may not be the only
determinant of the pattern of assembly and secretion of PDGF
isoforms. The induction of PDGF genes by several peptide
growth factors raises the possibility that endogenous PDGF
may mediate, at least partially, the mitogenic effect of these
peptides. This is particularly true since mesangial cells bind and
proliferate in response to exogenous PDGF. We have recently
demonstrated that the mitogenic effect of epidermal growth
factor (EGF), for example, may be mediated, at least partially,
by endogenous PDGF. Incubation of mesangial cells with EGF
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Table 1. Effects of PDGF on mesangial cells
I. Stimulation of DNA synthesis and cell proliferation
2. Stimulation of chemotaxis
3. Stimulation of contraction
4. Autoinduction of PDGF-A and -B chains
5. Stimulation of TGF-/3 production
Table 2. Potential sources of PDGF in the glomerulus
1. Infiltrating blood elements
platelets, monocytes macrophages
2. Intrinsic glomerular cells
mesangial cells
endotheial cells
Table 3. Regulation of PDGF production in mesangial cells
Positive regulators Negative regulators
Growth factors:
PDGF, EGF, FGF, TGF-a,
TNF, TGF-J3
Vasoactive compounds:
Ang II, endothelin, thrombin
Phospholipids:
phosphatidic acid (PA)
phosphatidylserine (PS)
Lipoproteins: LDL, VLDL
Protein kinase C agonists:
PMA, bryostatin
Forskolin
Phosphodiesterase inhibitors
cAMP analogues
Adenylate cyclase agonists:
iloprost
in the absence and presence of anti-PDGF antibodies demon-
strates that PDGF antibody partially blocks the mitogenic effect
of EGF. This effect appears to be specific since control IgG
does not block the mitogenic effect of EGF [7]. It remains to be
determined whether PDGF mediates the mitogenic effect of
other peptide growth factors. We have also observed that the
addition of antibody that recognizes PDGF A and B chains
lowers basal thymidine incorporation in mesangial cells, sug-
gesting that PDGF may act in an autocrine fashion even in cells
that are not stimulated by exogenous mitogens.
Molecular cloning of mouse and human PDGF receptors
cDNA have shown structural similarity with other protein
tyrosine kinase receptors [3, 4, 11]. These studies also demon-
strated the presence of two distinct PDGF receptor genes that
encode alpha and beta receptor subunits [12, 14]. PDGF A and
B chains bind the alpha subunit whereas the PDGF-B chain
binds the beta subunit. The proposed model for PDGF is that
each chain of the PDGF dimer binds an individual receptor and
promotes dimeriazation [121. Thus PDGF AA dimerizes alpha
alpha PDGF receptors. PDGF AB dimerizes alpha alpha or
alpha beta PDGF receptors and PDGF BB may form alpha
alpha, alpha beta or beta beta receptor dimers. We have
recently compared the mitogenic effect of all three isoforms in
human mesangial cells. PDGF BB as well as AB elicited a
strong mitogenic response while PDGF AA had no effect in
human mesangial cells. Our preliminary studies suggest that the
lack of responsiveness to PDGF AA homodimer is likely due to
down regulation of PDGF alpha receptor in these cells. When
human mesangial cells are preincubated with suramin, a com-
pound that prevents the binding of PDGF to its receptor, then
washed and exposed to PDGF AA homodimer, a small but
consistent increase in DNA synthesis is observed. These find-
ings suggest that mesangial cell PDGF alpha receptor is down
regulated by endogenous PDGF. Moreover, our data suggested
the predominance of beta receptors in mesangial cells. The
mitogenic effect of both isoforms BB and AB correlates with
their effect to activate phosphalipase C with subsequent gener-
ation of 1P3 and cytosolic calcium. The mitogenic effect also
correlates well with the ability of both isoform BB and AB, but
not AA, to induce PDGF A and B chain mRNA. The near
equivalent response of mesangial cells to the mitogenic effect of
both BB and AB dimers correlates with their ability to induce
phospholipase C with subsequent increase in 1P3 and cytosolic
calcium. Moreover, it correlates with their ability to induce
PDGF A and B chain mRNAs. These data also suggest that
very few PDGF alpha receptors do not mediate mitogenic effect
alone, but they do when dimerized with a beta receptor in the
presence of an AB ligand [3, 4]. The presence of very few alpha
receptors in mesangial cells which express very high amounts of
PDGF A chain mRNA likely represents a mechanism that
prevents autocrine growth of these non-transformed cells [3]. It
is likely that the PDGF beta receptor is the major target for
PDGF in the glomerulus and specifically in mesangial cells.
Recent in vitro studies in other cell systems as well as in
mesangial cells demonstrate an important regulatory role for
PDGF receptors in modulating the effect of other peptides. Up
or down regulation of PDGF alpha or beta receptors in response
to TGF-beta, for example, may explain some of the complex
effects of this peptide on cells that produce one or more of
PDGF isoforms [12].
In addition to its mitogenic effect, PDGF is a potent chemo-
attractant for mesangial cells. Barnes and Hevey [13] have
clearly demonstrated that rat mesangial cells migrate in re-
sponse to PDGF purified from human platelets which is pre-
dominantly an AB heterodimer.
PDGF has been demonstrated to elicit contraction or relax-
ation in different vascular beds. This is likely to be dependent
on whether the endothelial cells lining such vessels express
receptors for PDGF, in which case the release of endothelium-
derived relaxing factor may determine the net effect of PDGF.
Menè et al [5] reported that PDGF contracts mesangial cells.
PDGF therefore may influence glomerular hemodynamics. The
ultimate effect of PDGF on determinants of glomerular filtration
rate, however, has to take into consideration its effect on
afferent and efferent arteriolar tones. Infusion of PDGF into the
isolated microperfused glomerulus results in marked increase in
intraglomerular capillary pressure associated with decrease in
flow rate and marked increase in resistance.
PDGF may regulate matrix metabolism in mesangial cells
either directly or through release of other growth factors. We
have recently found that PDGF stimulates release of TGF-beta
by mesangial cells. The relative expression of PDGF and
activation of TGF-beta may be an important determinant of the
nature of the glomerular lesion, that is, proliferation and/or
sclerosis. There is increasing evidence that PDGF may play a
role in inflammatory and proliferative glomerular diseases.
Increased expression of PDGF has been demonstrated in gb-
meruli from patients with lupus nephritis. Moreover, expres-
sion of PDGF beta type receptor is increased in vascular
smooth muscles from atherosclerotic plaques as well as from
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rejected kidneys [14, 15]. Gesualdo et a! [16] and lida et a! [17]
demonstrated increased expression of PDGF in experimental
animals with proliferative glomerular diseases as well as in
human kidney biopsies obtained from patients with a variety of
proliferative lesions. In two models of IgA riephropathy, in-
creased expression of PDGF and PDGF B chain mRNA in
kidneys from diseased mice was demonstrated by immunohis-
tochemical techniques and by solution hybridization assay,
respectively [161. PDGF was localized primarily within mesan-
gial areas of glomeruli and to a lower extent in the interstitium.
The increased PDGF expression correlated with the degree of
hypercellularity and clinical features of the disease. Increased
expression of PDGF also was demonstrated in glomeruli from
patients with proliferative glomerular diseases such as lupus
nephritis, and IgA nephropathy but not minimal chain disease.
lida and his colleagues [17] demonstrated marked increase in
the expression of PDGF B chain as well as PDGF beta receptor
mRNAs and their translated proteins in glomenili from rats with
severe proliferative lesions that follow mesangial cell lysis
induced by anti-thyl antibodies. The increased expression of
both the protein and its receptor suggest that PDGF may play a
role in the pathogenesis of cell proliferation in these diseases.
Detailed chronologic studies correlating growth factor expres-
sion with the severity of proliferative or sclerotic lesions are
needed. Such studies will help establish temporal relationship
between growth factor expression and pathologic manifestation
thereby facilitating design regimens where receptor antagonists
or antibodies to specific growth factors could be utilized to
neutralize or abolish some of the manifestations of the disease
process [18].
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